Neurotoxicity Syndromes
7
1
2
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
28.6%
2 terminated out of 7 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
200%
2 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy
To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity
Assessing DCog Short for Neurotoxicity in CAR-T
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
Scopolamine Treatment for Patients With Organophosphate Poisoning
A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity